CAR-T cell therapy for severe autoimmune diseases
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis
- Your disease is not well controlled by at least two standard treatments, or you need a high dose of steroids (over 15 mg prednisone daily)
- Your overall health is good enough for daily activities (ECOG score 0 or 1)
- Your heart, lungs, kidneys, liver, and blood counts are within safe ranges
- You have not had CAR-T therapy before, and you do not have an active infection or certain viral infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This early-phase trial tests a new cell therapy called JY231 for people with severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or ANCA vasculitis that haven't improved with standard treatments. It aims to see if the therapy can help control the disease when other options have failed.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with certain autoimmune diseases, including lupus, scleroderma, and others. The goal is to see if the treatment can help control the disease.
This trial tests whether CAR-T cells, a type of immune cell therapy, can help people with certain autoimmune diseases. If you have lupus, scleroderma, or other listed conditions, you may be able to join and see if this treatment can calm your overactive immune system.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.